While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...
As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
The National Medical Products Administration (NMPA) has cleared the drug for triple-negative breast cancer (TNBC), making it ...
Zacks.com on MSN1d
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...
Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback